DOCSLIB.ORG

Dec 06 NUCLEUS Corrected

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dec 06 NUCLEUS Corrected DED 8-199 UN 18 189 8 O 98 F yyyy N N yyyy Y Y O O T T R R E E I I T T C H C H E O E O yyyyN N A E S A E S S S S L S L T T A A E A E A C C R C I R C I yyyyN S M N S M S E S E E H E H C C C C T N T N IO A December 2006IO A Vol. LXXXV, No. 4 yyyyC C N • AMERI N • AMERI Monthly Meeting Making the Connection Medicinal Chemistry Symposium: “New An Article on Good Hiring Practices Approaches on Depression” by Megan Driscoll, Jennifer Sass and Scott Szczesny Book Review Report from NERM “Leaps in the Dark. The Making Of Scientific 2006 Reputations” by John Waller. Reviewed by Dennis Sardella By Morton Z. Hoffman featured a chemist, an environmental logistics. The Board elected Christo- Report from activist, a local newspaper reporter, a pher Masi (Westfield State College; public health specialist, and a local Central Massachusetts Local Section) member of the New York State Assem- and Wayne Jones to two-year terms NERM 2006 bly, who discussed the ramification of (starting 1/1/07) as Secretary and Trea- Morton Z. Hoffman, the TCE spill at the IBM manufactur- surer, respectively; they will replace Boston University ing site; the career services provided Willem Leenstra (University of Ver- NESACS Representative to the Board by the ACS Chemjobs Career Center, mont; Green Mountain Local Section), of Directors, Northeast Region of the who has held the combined positions ACS, Inc. since the incorporation of the North- east Region in 2005. Continuing as The 34th Northeast Regional ACS Chair and Vice Chair of the Board until Meeting was held in Binghamton, NY, the end of 2007 will be Julianne Smist on October 5-7, 2006. Hosted by the (Springfield College; Connecticut Val- Binghamton Local Section, the meet- ley Local Section) and Richard Cobb ing had “Emerging Technologies and (Rochester Local Section), respec- the Chemical Sciences” as its theme, tively. The Board voted to participate and offered 554 presentations; more in the Division of Chemical Education than 850 registrants, including 120 (l-r) Wayne Jones(Binghamton University), Tobin Marks (Northwestern University), Ann undergraduate students, were in atten- Nalley (ACS President) dance. With numerous grants to sup- photo by Morton Z. Hoffman port programs within the meeting, which included career workshops, more than 20 exhibitors, many organi- résumé reviews, and the use of the zational supporters, and a very strong Career Center database by job seekers; program, the meeting was the best a symposium for K-12 teachers that attended NERM (and one of the most attracted more than 40 attendees. The profitable) in recent years. Among the details of the meeting program and attendees from ACS governance were the abstracts of the papers can be James Burke (Chair of the Board of found at http://www.nerm2006.org/. Richard Cobb (Eastman Kodak), at right, win- ner of theRegional Award for Volunteer Service, Directors), Anne O’Brien (District I The following were honored at the receiving congratulations from Morton Hoffman Director), Ann Nalley (President), and awards reception and dinner: Brenda (Boston University), designated recipient of the Catherine Hunt (President-Elect); also From (Manhattan High School for 2007 Award for Volunteer Service to the ACS. present were three of the four current Girls, New York, NY), Excellence in photo from Morton Z. Hoffman candidates for President-Elect High School Chemistry Teaching Regional High School Teacher Award. (Rhodes, Shakhashiri, and Walsh). Award; Richard Cobb (Eastman A preliminary bid from the Connecti- Kodak), Regional Award for Excel- cut Valley Local Section to host lence in Volunteer Service; Kenneth NERM 2009 in Hartford, CT , or Takeuchi (University of Buffalo), Stan- Springfield, MA, was received; a full ley C. Israel Regional Award for proposal from the Northern New York Advancing Diversity in the Chemical Local Section to host NERM 2010 in Sciences; Voya Markovich (Endicott Potsdam, NY, was accepted. The idea Interconnect Technologies), Patricia of holding the 2011 NERM jointly Burns, Grazyna Kmieciek-Lawrynow- with the Middle Atlantic Regional icz, Hwee Ng, and Chieh-Min Cheng Meeting (MARM) at a site near the (all of Xerox), Regional Industrial border of the two regions ( e.g., (l-r) Ann Nalley (ACS President), Anne O’Brien Innovation Award. Westchester County, NY) was favor- (District I Director), Katie Hunt (ACS Presi- The Board of Directors of the ably discussed; local sections in the dent-Elect) photo by Morton Z. Hoffman Northeast Region, Inc., held its annual Northeast Region are invited to Notable in the program were the meeting on October 7 at which time it express interest to serve as a host. following features: the keynote lecture unanimously voted to commend Inasmuch as there will be no NERM in by Tobin Marks (Northwestern Univer- Wayne Jones (Binghamton University; 2007, the Board will next meet at the sity) on “New Materials and Processes Binghamton Local Section), the Gen- Boston ACS meeting. for Organic Transistors, Inorganic eral Chair of NERM 2006, for leading NERM 2008 will be hosted by the Transistors, and Printed Electronics;” the organizing committee of this very Green Mountain Local Section on June the public interest symposium on “Liv- successful NERM and for engaging the 29-July 2 in Burlington, VT. See ing in a Chemical World: Trichloroeth- more than 60 volunteers who worked <http://www.nerm2008.org/> for ylene (TCE) in Endicott, NY,” which on various aspects of the meeting details. N 2 The Nucleus December 2006 The Northeastern Section of the American Chemical Society, Inc. Contents Office: Marilou Cashman, 23 Cottage St., Natick, MA 01360. 1-800-872-2054 (Voice or FAX) or 508-653-6329. Report from NERM 2006 ________________________________2 e-mail: mcash0953(at)aol.com By Morton Z. Hoffman. Photos by Morton Z. Hoffman Any Section business may be conducted via the business office above. Book Review by Dennis Sardella___________________________4 NESACS Homepage: http://www.NESACS.org Leaps in the Dark. The Making of Scientific Reputations, by John Waller Sathish Rangarajan, Webmaster ACS Hotline, Washington, D.C.: Monthly Meeting _______________________________________5 1-800-227-5558 Medicinal Chemistry Symposium: New Approaches on Depression Officers 2006 Chair: Chemists in the Community ______________________________8 Patricia Mabrouk ACS leadership and members help out at San Francisco Meeting by Lee Latimer Chemistry Department, Northeastern University Boston, MA 02115 2007 National ACS Award Winners from NESACS ____________8 613 373 2845; p.mabrouk(at)neu.edu Chair-Elect: Call for Nominations____________________________________9 Mukund Chorghade James Flack Norris Award, Philip L. Levins Memorial Prize 14 Carlson Circle, Natick, MA 01360-4205 508-651-7809 and 508-308-3891 Making the Connection 10 Chorghade(at)comcast.net _________________________________ Immediate Past Chair: An article on good hiring practices by Megan Driscoll, Jennifer Sass and Amy Tapper Scott Szezesny of PharmaLogics Recruiting Peptimmune 64 Sidney Street, Suite 380, Chemists in the Community _____________________________14 Cambridge, MA 02139 613-715-8005; amy.tapper(at)peptimmune.com NESACS Member Helps at San Francisco Zoo Secretary: Student Affiliate Chapters Honored 14 Michael Singer _______________________ Sigma-Aldrich 3 Strathmore Rd. Natick, MA 01360-2447 Pictures from the September and October Meetings _________16 508-651-8151x291 msinger(at)sial.com By Morton Z. Hoffman, James Phillips and Venu Neelagiri Treasurer: James Piper Cover: Meeting of Argentinian and American journal donation collaborators, 19 Mill Rd., Harvard, MA 01451 Professor Maximo Baron (r) and Daniel Eustace (NESACS) in Buenos Aires at 978-456-3155 piper28(at)attglobal.net AQA headquarters on October 10, 2006. Dan’s article on journal donations in Auditor: Anthony Rosner the Summer edition of the Nucleus prompted a member to donate 40 years of J. Archivist: Phys. Chem. and J. Electrochem. to the AQA. Prof. Baron is now trying to figure Myron S. Simon out how to transport the collection to Argentina. Photo provided by Dan Eustace. 20 Somerset Rd. Newton, MA 02465; 613-332-5273 Deadlines: February 2007 Issue: December 8, 2006 romysimon(at)mindspring.com Trustees: March 2007 Issue: January 10, 2007 Joseph A. Lima, Esther A.H. Hopkins, Michael E. Strem Councilors Alternate Councilors Term Ends 12/31/2006 Michaeline F. Chen Wallace J. Gleekman Catherine E. Costello Howard R. Mayne The Nucleus is distributed to the members of the Northeastern Section of the American Chemical Patricia A. Mabrouk Alfred Viola Society, to the secretaries of the Local Sections, and to editors of all local A.C.S. Section publications. Julia H. Miwa Barbara G. Wood Forms close for advertising on the 1st of the month of the preceding issue. Text must be received by the Dorothy J. Phillips David Warr editor six weeks before the date of issue. Term Ends 12/31/2007 Editor: Michael P. Filosa, editor, Ph.D., ZINK Imaging Incorporated, 1265 Main Street, Thomas R. Gilbert Arlene W. Light Michael J. Hearn Timothy B. Frigo Waltham, MA 02451 Email: Michael.Filosa(at)zink.com; Tel: 781-386-8479. Michael Singer Mary Mahaney Associate Editors: Myron S. Simon, 20 Somerset Rd., W. Newton, MA 02465, Tel: 613-332-5273 Pamela Nagafuji Mark Froimowitz Nancy Simons, Analytical Chemist, Corporate R&D, Boston Scientific Corp., Term Ends 12/31/2008 1 Boston Scientific Place A4, Natick, MA 01360-1537. Doris I. Lewis Patrick M. Gordon Email: Nancy.Simons(at)bsci.com; Tel. 508-650-8603; Fax 508-647-2329 Morton Z. Hoffman Michael P. Filosa Sheila E Rodman, Konarka Techologies Inc., 116 John St. Suite 12, Lowell, MA Christine Jaworek-Lopes Lawrence Scott Mary Burgess Liming Shao 01852 email:srodman(at)konarka.com tel 978-569-1414 Donald O.
Load more

Recommended publications
  • BMC Pharmacology Biomed Central
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Springer - Publisher Connector BMC Pharmacology BioMed Central Research article Open Access Pharmacological Properties of DOV 315,090, an ocinaplon metabolite Dmytro Berezhnoy†1, Maria C Gravielle†1, Scott Downing1, Emmanuel Kostakis1, Anthony S Basile2, Phil Skolnick2, Terrell T Gibbs1 and David H Farb*1 Address: 1Laboratory of Molecular Neurobiology, Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, 715 Albany St., Boston, MA 02118, USA and 2DOV Pharmaceutical, Inc, 150 Pierce St., Somerset, NJ 08873-4185, USA Email: Dmytro Berezhnoy - [email protected]; Maria C Gravielle - [email protected]; Scott Downing - [email protected]; Emmanuel Kostakis - [email protected]; Anthony S Basile - [email protected]; Phil Skolnick - [email protected]; Terrell T Gibbs - [email protected]; David H Farb* - [email protected] * Corresponding author †Equal contributors Published: 13 June 2008 Received: 20 December 2007 Accepted: 13 June 2008 BMC Pharmacology 2008, 8:11 doi:10.1186/1471-2210-8-11 This article is available from: http://www.biomedcentral.com/1471-2210/8/11 © 2008 Berezhnoy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background: Compounds targeting the benzodiazepine binding site of the GABAA-R are widely prescribed for the treatment of anxiety disorders, epilepsy, and insomnia as well as for pre- anesthetic sedation and muscle relaxation. It has been hypothesized that these various pharmacological effects are mediated by different GABAA-R subtypes.
    [Show full text]
  • Failed Trials for Central Nervous System Disorders Do Not Necessarily
    CORRESPONDENCE LINK TO ORIGINAL ARTICLE funding often outweighs the efforts required to rigorously challenge the novel findings; Failed trials for central nervous system thus, verification in an independent laboratory is unlikely. disorders do not necessarily invalidate As the costs of clinical studies are so much higher than those of preclinical development, preclinical models and drug targets one might assume that pharmaceutical com- panies would conduct robust replications of key findings. This is indeed the case during Anton Bespalov, Thomas Steckler, Bruce Altevogt, Elena Koustova, Phil Skolnick, lead optimization, candidate selection, test- Daniel Deaver, Mark J. Millan, Jesper F. Bastlund, Dario Doller, Jeffrey Witkin, ing different administration routes and the Paul Moser, Patricio O’Donnell, Ulrich Ebert, Mark A. Geyer, Eric Prinssen, use of primary preclinical disease models. Theresa Ballard and Malcolm Macleod However, this is far less common for stud- ies in the more complex disease models that are used in late stages of development and A recent article identified five key technical modest effects on survival. Numerous other are potentially more relevant for predicting determinants that make substantial contribu- drug candidates have reported efficacy in a clinical efficacy. tions to the outcome of drug R&D projects superoxide dismutase 1 (SOD1) mouse model In general, the rigorousness with which (Lessons learned from the fate of AstraZeneca’s of ALS (one of the common animal models preclinical data is obtained — and the result- drug pipeline: a five-dimensional framework. for this disease), but none of these candidates ing robustness of the data — is quite low; Nat. Rev. Drug Discov. 13, 419–431 (2014))1.
    [Show full text]
  • The Opioid Epidemic: Crisis and Solutions
    PA58CH09-Skolnick ARI 18 November 2017 9:40 Annual Review of Pharmacology and Toxicology The Opioid Epidemic: Crisis and Solutions Phil Skolnick Opiant Pharmaceuticals, Santa Monica, California 09401, USA; email: [email protected] Annu. Rev. Pharmacol. Toxicol. 2018. 58:143–59 Keywords First published as a Review in Advance on heroin, overdose, naloxone, vaccines, medication-assisted therapies, pain October 2, 2017 The Annual Review of Pharmacology and Toxicology Abstract by [email protected] on 01/16/18. For personal use only. is online at pharmtox.annualreviews.org The widespread abuse of prescription opioids and a dramatic increase in https://doi.org/10.1146/annurev-pharmtox- the availability of illicit opioids have created what is commonly referred to 010617-052534 as the opioid epidemic. The magnitude of this epidemic is startling: About Copyright c 2018 by Annual Reviews. 4% of the adult US population misuses prescription opioids, and in 2015, Annu. Rev. Pharmacol. Toxicol. 2018.58:143-159. Downloaded from www.annualreviews.org All rights reserved more than 33,000 deaths were attributable to overdose with licit and illicit opioids. Increasing the availability of medication-assisted treatments (such as buprenorphine and naltrexone), the use of abuse-deterrent formulations, and ANNUAL REVIEWS Further the adoption of US Centers for Disease Control and Prevention prescribing Click here to view this article's guidelines all constitute short-term approaches to quell this epidemic. How- online features: • Download figures as PPT slides ever, with more than 125 million Americans suffering from either acute or • Navigate linked references • Download citations chronic pain, the development of effective alternatives to opioids, enabled at • Explore related articles • Search keywords least in part by a fuller understanding of the neurobiological bases of pain, offers the best long-term solution for controlling and ultimately eradicating this epidemic.
    [Show full text]
  • Bfm:978-3-0348-8470-9/1.Pdf
    Milestones in Drug Therapy MDT Series Editors Prof. Dr. Michael J. Pamham Prof. Dr. J. Bruinvels PLIVA INFARM Research Institute Sweelincklaan 75 Prilaz baruna Filipovica 25 NL-3723 JC Bilthoven 10000 Zagreb The Netherlands Croatia Anxiolytics Edited by M. Briley and D. Nutt Springer Basel AG Editors Dr. Mike Briley Professor David Nutt Institut de Recherche Pierre Fabre University of Bristol Parc Industriei de la Chartreuse Psychophannacology Unit 8 I 100 Castres School of Medical Science France University Walk Bristol BS8 ITD UK Library of Congress Cataloging-in-Publication Data Anxiolytics / edited by M. Briley and D. NuU, p. cm - Milestones in drug therapy) lncludes bibliographical references and index. ISBN 978-3-0348-9581-1 ISBN 978-3-0348-8470-9 (eBook) DOI 10.1007/978-3-0348-8470-9 1. Tranquilizing drugs. 1. Briley, M. II. Nutt, David J., 1951- III. Series. RM333 A582 2000 615'.7882--{jc2I 00-033748 Deutsche Bibliothek Cataloging-in-Publication Data Anxiolytics / ed. by M. Briley and D. Nutt. - Basel ; Boston; Berlin: Birkhiiuser, 2000 (Milestones in drug therapy) ISBN 978-3-0348-9581-1 ISBN 978-3-0348-9581-1 The publisher and editor can give no guarantee for the infonnation an drug dosage and administration contained in this publication. The respective user must check its accuracy by consulting other sources of reference in each individual case. The use of registered names, trademarks etc. in this publication, even if not identified as such, does not imply that they are exempt from the relevant protective laws aud regulations or free for general use. This work is subject to copyright.
    [Show full text]
  • Beyond Monoamine-Based Therapies: Clues to New Approaches
    Beyond Monoamine-Based Therapies: New Approaches Beyond Monoamine-Based Therapies: Clues to New Approaches Phil Skolnick, Ph.D. Advances in antidepressant therapy have resulted in agents with fewer serious side effects than, for example, nonselective monoamine oxidase inhibitors and tricyclic antidepressants. Nonetheless, these © Copyrightnewer agents are far from 2002 the ideal. Physicians Many of the drawbacks Postgraduate associated with these newer Press, agents—slow Inc. onset, low rate of response, and low rate of remission—are likely to be mechanism related. In order to overcome these problems, researchers must either improve upon these traditional, biogenic amine– based mechanisms or explore nontraditional mechanisms. Strategies for improving biogenic amine– based antidepressants include the so-called serotonin augmentation strategy and the broad spectrum agent that simultaneously blocks reuptake at the serotonin, norepinephrine, and dopamine transport- ers. Two nontraditional approaches employ modulation of glutamate receptor function. At face value, these glutamate-based approaches (N-methyl-D-aspartate [NMDA] antagonists and α-amino-3- hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] receptor potentiators) appear diametrically opposed. However, these 2 mechanisms may ultimately impact similar cellular endpoints. (J Clin Psychiatry 2002;63[suppl 2]:19–23) One personal copy may be printed dvances in antidepressant treatment have resulted in generally termed serotonin augmentation. This strategy is Aagents that are safer and easier to use than, for based on the hypothesis that the delayed onset of seroto- example, nonselective irreversible monoamine oxidase in- nin-based agents (including selective serotonin reuptake hibitors (MAOIs) and tricyclics (TCAs). These newer inhibitors [SSRIs] and TCAs such as imipramine) is agents are far from ideal.
    [Show full text]
  • Virginia Drug Discovery Consortium Virginiabrainrx: a Symposium on Drug Discovery for the Brain
    Virginia Drug Discovery Consortium VirginiaBrainRx: A Symposium on Drug Discovery for the Brain May 23 - 24, 2016 Omni Richmond Hotel Richmond, Virginia Welcome letter May 23, 2016 Dear Symposium Participants: On behalf of the Organizing Committee, it is my great pleasure to welcome you to Richmond and to the VirginiaBrainRx Symposium. This Symposium includes five keynote lectures and several invited lectures from distinguished scientists, and also features poster presentations by scientists from around the Commonwealth. One of the major purposes of this Symposium is to provide networking opportunities that could foster new inter-university and public-private collaborative projects in brain drug-discovery. The NIH Roadmap for Research states “The scale and complexity of today’s … research problems increasingly demand that scientists move beyond the confines of their own discipline and explore new organizational models for team science….…”, and this Symposium has the goal of furthering such collaborations, especially when it comes to the discovery, development, and delivery of drugs to treat brain illness. The organizers hope that everyone will take advantage of the poster sessions and social times to meet new colleagues and to explore new collaborations. This Symposium is the first major public project of the fledgling irginia“V Drug Discovery Consortium.” This Consortium has the aim of fostering collaborative drug discovery research in all disease areas between Virginia’s universities and the pharmaceutical and biotech industries, and it plans to sponsor regular Symposia on different aspects of drug discovery, with the next one tentatively scheduled for Spring 2017. A short questionnaire is included in your registration materials, and I hope that you will take the time to complete this on Tuesday so as to guide the organizers in planning future Symposia.
    [Show full text]
  • Milestones in Drug Therapy
    Milestones in Drug Therapy Series Editors Michael J. Parnham, Director of Science & Technology, MediMlijeko d.o.o., Zagreb, Croatia Jacques Bruinvels, Bilthoven, The Netherlands Advisory Board J.C. Buckingham, Imperial College School of Medicine, London, UK R.J. Flower, The William Harvey Research Institute, London, UK A.G. Herman, Universiteit Antwerpen, Antwerp, Belgium P. Skolnick, National Institute on Drug Abuse, Bethesda, MD, USA For further volumes: http.//www.springer.com/series/4991 . Phil Skolnick Editor Glutamate-based Therapies for Psychiatric Disorders Volume Editor Phil Skolnick, Ph.D., D.Sc. (hon.) Director, Division of Pharmacotherapies & Medical Consequences of Drug Abuse National Institute on Drug Abuse 6001 Executive Boulevard Bethesda, MD 20892 USA [email protected] Series Editors Prof. Dr. Michael J. Parnham Director of Science & Technology MediMlijeko d.o.o. Pozarinje 7 HR-10000 Zagreb Croatia Prof. Dr. Jaques Bruinvels Sweelincklaan 75 NL-3723 JC Bilthoven The Netherlands ISBN 978-3-0346-0240-2 e-ISBN 978-3-0346-0241-9 DOI 10.1007/978-3-0346-0241-9 Library of Congress Control Number: 2010935790 # Springer Basel AG 2010 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcast- ing, reproduction on microfilms or in other ways, and storage in data banks. For any kind of use, permission of the copyright owner must be obtained. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protec- tive laws and regulations and therefore free for general use.
    [Show full text]
  • ASPET Preliminary Program for Experimental Biology 2003
    ASPET Preliminary Program for Experimental Biology 2003 Symposia Saturday Morning Inverse agonism: translation to in vivo function Chairs: James H. Woods and Richard Neubig Current status of inverse agonism as a pharmacological and therapeutic tool. Graeme Milligan, Univ. of Glasgow, Scotland Delta-opioid inverse agonists. Chris J. Evans, UCLA Inverse agonists in chemokine receptors. M.R. Brann, Acadia Pharmaceut. Inverse agonists and competitive antagonists in benzodiazepine dependent monkeys. Charles P. France, Univ. of Texas Hlth. Sci. Ctr., San Antonio Actions of hallucinogens and atypical antipsychotic drugs at serotonin receptors Chairs: Bryan L. Roth and David R. Sibley Atomic and molecular mechanisms of 5-HT2A receptor activation, targeting and trafficking. Bryan L. Roth, Case Western Reserve Univ. Med. Sch. RNA editing and genomic polymorphisms: relevance for schizophrenia, atypical antipsychotics and hallucinogens. Elaine Sanders-Bush, Vanderbilt Univ. Med. Sch. Functional roles of 5-HT2A receptors in the prefrontal cortex. Rodrigo Andrade, Wayne State Univ. Med. Sch. 5-HT2A receptors in psychosis and antipsychotic treatments: insights from knockout mice. Jay Gingrich, Columbia Univ. Serotonin 2C receptor distribution in the ventral tegmental area. Marcy J. Bubar, Univ. of Texas Med. Br. at Galveston (Abstract 3105) A pharmacology core curriculum: to be or not to be Chairs: Patricia B. Williams and Gregory D. Fink Introduction: More than facts: knowledge, skills and attitudes. Patricia B. Williams, Eastern Virginia Med. Sch. The knowledge objectives and essential drug list. Gary Rosenfeld, Univ. of Texas-Houston Med. Sch. A view from the top: a chairman speaks. Kenneth E. Moore, Michigan State Univ. Teaching medical school pharmacology in the 21st Century – can a core knowledge base be defined? Eric P.
    [Show full text]
  • Resource List
    National Institute of OPIOIDS AND THE WORKPLACE: Environmental Health Sciences Worker Training Program PREVENTION AND RESPONSE RESOURCE LIST Agency, Industry, Labor Union Information Federal Agency ■ National Institute of Environmental Health Sciences (NIEHS), National Clearinghouse for Worker Safety and Health Training. Illicit Drug Exposure. This page has links to the NIEHS “Prevention of Occupational Exposure to Fentanyl and Other Opioids” awareness-level training tool. https://tools.niehs.nih.gov/wetp/index.cfm?id=2562 ■ National Institute for Occupational Safety and Health (NIOSH). Opioids in the Workplace. This page has links to NIOSH field studies, guidelines, research, and data. https://www.cdc.gov/niosh/topics/opioids/default.html ■ National Institutes of Health (NIH), U.S. National Library of Medicine (NLM). Opioid Addiction and Treatment Health Information Resources. This page contains comprehensive and organized links to government information. https://envirotoxinfo.nlm.nih.gov/opiate-addiction-and-human-health.html#a2 Industry ■ 3M. Beyond Responding to Drug Overdoses: Keeping You Safe from Fentanyl. https://multimedia.3m.com/mws/media/1383737O/fentanyl-3m-whitepaper.pdf ■ Construction Industry Alliance for Suicide Prevention. http://www.cfma.org/news/content.cfm?ItemNumber=4570 ■ Dupont. Fentanyl and Other Opioids. http://www.dupont.com/products-and-services/personal-protective-equipment/chemical-protective- garments/articles/protection-against-fentanyl-opiods.html ■ Harris P. 2017. The opioid crisis and workplace safety. Cremation Association of North America Blog, 14 September. http://www.cremationassociation.org/blogpost/776820/284743/The-Opioid-Crisis-and-Workplace- Safety 1 Opioids and the Workplace National Institute of OPIOIDS AND THE WORKPLACE: Environmental Health Sciences Worker Training Program PREVENTION AND RESPONSE Labor Union ■ Association of Union Contractors.
    [Show full text]
  • Pharmacology of Ibogaine and Ibogaine-Related Alkaloids
    The Ibogaine Dossier. Pharmacology of Ibogaine https://ibogainedossier.com/alkaloids.html The Ibogaine Dossier Main | Search | Science | Opinion | Literature | Links | Treatment | Bookshop | Feedback Pharmacology of Ibogaine and Ibogaine-Related Alkaloids Piotr Popik , Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, NYU Conference on Ibogaine Poland Nov 5-6, 1999 and Phil Skolnick , Neuroscience Discovery, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA Appeared as Chapter #3, in "THE ALKALOIDS", Vol.52, pp. 197-231. 1998, San Diego, USA. ISBN 0-12-469552-3. Edited by G.A. Cordell. © 1998 by Academic Press Order The Alkaloids, Vol. 52 T. iboga roots Ibogaine is extracted from the bark of the root CONTENT I. INTRODUCTION II. HISTORICAL OVERVIEW. III. CHEMICAL STRUCTURE AND PROPERTIES. IV. PHARMACOKINETICS. V. GENERAL PHARMACOLOGICAL ACTIONS. A. Animal Studies 1. Locomotor activity. a. Effects on locomotor activity induced by other drugs 2. Tremor. 3. Anxiety and fear. 4. Effects on self-administration of other drugs. 5. Effects on drug dependence. 6. Pain and analgesia. 7. Aggression. 8. Interoceptive properties. 9. Reinforcing effects. 10. Effects on learning and memory. 11. Cardiovascular actions. B. Human Studies. VI. LETHALITY AND NEUROTOXIC EFFECTS. VII. EFFECTS ON SPECIFIC NEUROTRANSMITTER SYSTEMS A. Ibogaine Effects on Dopaminergic Systems. 1. Dopaminergic effects: Pharmacological Specificity. 2. Ibogaine alters the effects of abused drugs on dopaminergic systems. B. Opioid Systems C. Serotonergic Systems. D. Calcium Regulation. 1 of 30 1/20/2019 6:13 AM The Ibogaine Dossier. Pharmacology of Ibogaine https://ibogainedossier.com/alkaloids.html E. Cholinergic Systems. F. Gamma-Aminobutyric Acidergic [GABAergic] Systems. G.
    [Show full text]
  • Elsevier Editorial System(Tm) for Trends in Pharmacological Sciences Manuscript Draft
    Elsevier Editorial System(tm) for Trends in Pharmacological Sciences Manuscript Draft Manuscript Number: TIPS-D-09-00098R1 Title: Glutamate Based Antidepressants: 20 Years On Article Type: Opinion Keywords: N-methyl-D-aspartate receptors; NMDA antagonists; depression; antidepressants; glutamate; ionotropic glutamate receptors; metabotropic glutamate receptors Corresponding Author: Dr Phil Skolnick, Corresponding Author's Institution: New York University Langone Medical Center First Author: Phil Skolnick Order of Authors: Phil Skolnick; Piotr Popik, M.D., Ph.D.; Ramon Trullas, Ph.D. Abstract: Depression is a chronic, recurring illness that affects more than 120 million people worldwide. Drugs increasing the synaptic availability of serotonin and norepinephrine (biogenic amine-based agents) have been used to treat depression for more than 50 years. However, significant symptom improvement requires ≥2-4 weeks of treatment, and a first course of therapy provides symptom relief to only 60-65% of patients. Roche and Evotec recently announced plans to develop N- methyl-D-aspartate (NMDA) receptor antagonists targeting the NR2B subtype for treatment resistant depression. This announcement closely follows a report that another NR2B antagonist, traxoprodil (CP 101,606), is antidepressant in patients unresponsive to a serotonin selective reuptake inhibitor (SSRI) as well as reports of rapid and sustained antidepressant effects following a single injection of the NMDA antagonist, ketamine. Here we describe evidence that glutamate-based therapies may represent an effective alternative to biogenic-amine based agents for depression, and provide perspectives on developing these agents. Cover letter Department of Behavioral Neuroscience and Drug Development tel: (+48+12) 6623375, fax: (+48+12) 6374500, e-mail: [email protected] Kraków, August 30, 2009 Dr.
    [Show full text]
  • Ketamine for Treatment-Resistant Depression Sanjay J
    Ketamine for Treatment-Resistant Depression Sanjay J. Mathew • Carlos A. Zarate Jr. Editors Ketamine for Treatment- Resistant Depression The First Decade of Progress Editors Sanjay J. Mathew Carlos A. Zarate Jr. Psychiatry and Behavioral Sciences Experimental Therapeutics and Baylor College of Medicine Pathophysiology Branch Michael E. Debakey VA Medical Center National Institute of Mental Health Houston , Texas National Institutes of Health USA Bethesda , Maryland USA ISBN 978-3-319-42923-6 ISBN 978-3-319-42925-0 (eBook) DOI 10.1007/978-3-319-42925-0 Library of Congress Control Number: 2016960037 © Springer International Publishing Switzerland (outside the USA) 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]